Status:
UNKNOWN
Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract
Lead Sponsor:
RenJi Hospital
Collaborating Sponsors:
Peking University First Hospital
Conditions:
Lymph Node Dissection
Eligibility:
All Genders
15-80 years
Phase:
PHASE2
Brief Summary
Recent studies showed the therapeutic benefit of lymphadenectomy in advanced stage urothelial carcinoma of the upper urinary tract, but there is still a lack of prospective studies. Thus, the current ...
Eligibility Criteria
Inclusion
- clinically diagnosed with upper tract urothelial carcinoma
- have no distant metastasis
- have an Eastern Cooperative Oncology Group (ECOG) score 0 to 2
- expected to receive radical nephroureterectomy
Exclusion
- a prior history of bladder cancer
- administration of neoadjuvant chemotherapy
- deny to receive long term follow-up
- patients with contralateral UTUCs
- patients with synchronous muscle invasive bladder cancer
Key Trial Info
Start Date :
February 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 22 2023
Estimated Enrollment :
504 Patients enrolled
Trial Details
Trial ID
NCT03474926
Start Date
February 22 2018
End Date
February 22 2023
Last Update
May 22 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijin, Beijin, China, 100034
2
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China, 200123